Effect of YM‐53601, a novel squalene synthase inhibitor, on the clearance rate of plasma LDL and VLDL in hamsters
Authors:
- 1 October 2002
- journal article
- Published by Wiley in British Journal of Pharmacology
- Vol. 137 (4) , 561-567
Abstract
To better understand how it decreases plasma cholesterol and triglyceride, we evaluated the effect of YM‐53601 ((E‐2‐[2‐fluoro‐2‐(quinuclidin‐3‐ylidene) ethoxy]‐9H‐carbozole monohydrochloride) on the clearance rate of low density lipoprotein (LDL) and very low density lipoprotein (VLDL) in hamsters. Treatment with YM‐53601 at 50 mg kg−1 for 5 days in hamsters fed a normal diet enhanced the disappearance of 1,1′‐Dioctadecyl‐3,3,3′,3′‐tetramethylindocarbocyanine perchlorate (DiI)‐VLDL and DiI‐LDL. This effect on DiI‐LDL was lost in the early phase after DiI‐methyl(met)‐LDL, chemically modified to block LDL receptor binding, was injected in hamsters, but was retained in the late phase. Pre‐treatment with protamine sulphate, which inhibits the activity of LPL, also failed to enhance DiI‐VLDL clearance rate by YM‐53601. Even on single oral administration at 30 mg kg−1, YM‐53601 enhanced the disappearance of the high concentration of plasma triglyceride after injection of intrafat, an emulsion of fat. Plasma triglyceride was significantly decreased as soon as 1 h after single administration of YM‐53601 in hamsters fed a normal diet. These results indicate that the decrease in plasma total cholesterol and triglyceride after the treatment with YM‐53601 is due to its enhancement of the clearance rate of LDL and VLDL, respectively. Moreover, YM‐53601 may be effective in decreasing plasma triglyceride levels early in the course of treatment of hypertriglyceridaemia in humans. British Journal of Pharmacology (2002) 137, 561–567. doi:10.1038/sj.bjp.0704906Keywords
This publication has 24 references indexed in Scilit:
- YM‐53601, a novel squalene synthase inhibitor, reduces plasma cholesterol and triglyceride levels in several animal speciesBritish Journal of Pharmacology, 2000
- Inhibitors of Cholesterol Biosynthesis Increase Hepatic Low-Density Lipoprotein Receptor Protein DegradationArchives of Biochemistry and Biophysics, 1996
- Effect of Squalene Synthase Inhibition on the Expression of Hepatic Cholesterol Biosynthetic-Enzymes, LDL Receptor, and Cholesterol 7α HydroxylaseArchives of Biochemistry and Biophysics, 1994
- The novel compound NO-1886 increases lipoprotein lipase activity with resulting elevation of high density lipoprotein cholesterol, and long-term administration inhibits atherogenesis in the coronary arteries of rats with experimental atherosclerosis.Journal of Clinical Investigation, 1993
- Comparison of clofibrate and caloric restriction on kinetics of very low density lipoprotein triglycerides.Arteriosclerosis: An Official Journal of the American Heart Association, Inc., 1985
- Contribution of the receptor pathway to low density lipoprotein catabolism in humans. New methods for quantitation.Arteriosclerosis: An Official Journal of the American Heart Association, Inc., 1984
- Influence of gemfibrozil and clofibrate on metabolism of cholesterol and plasma triglycerides in man1984
- The lipid-lowering profile in rodents AZ-1355, A New Dibenzoxazepine DerivativeAtherosclerosis, 1981
- Determination of free amino groups in proteins by trinitrobenzenesulfonic acidAnalytical Biochemistry, 1966
- Studies on the Elimination of Exogenous Lipids from the Blood Stream. The Kinetics of the Elimination of a Fat Emulsion and of Chylomicrones in the Dog after Single InjectionActa Physiologica Scandinavica, 1963